Statement of Principles concerning carotid artery disease (Reasonable Hypothesis) (No. 54 of 2020)

This SoP rests on a set of precise conceptual choices that determine what evidence and connections will operate as the minimal medical basis for a “reasonable hypothesis” linking carotid artery disease to service. The principal concepts, with the primary statutory references, are as follows.

• Definition of the condition: “Carotid artery disease” is defined substantively in s 7(2) to mean occlusion, stenosis, aneurysm, dissection or arteriovenous fistula of the common, internal or external carotid artery that warrants medical treatment, and the definition expressly includes carotid atherosclerosis and non‑atherosclerotic carotid artery disease. The instrument notes ICD‑10‑AM codes that capture the condition (s 7(3)-(4)), but makes plain that the legal meaning is the statutory definition in s 7(2).

• Inclusion of death: death from carotid artery disease is captured where death results from a terminal event or condition that was contributed to by carotid artery disease (s 7(5)). “Terminal event” is defined in Schedule 1 (for example, pneumonia, cardiac arrest, circulatory failure, cessation of brain function).

• The “reasonable hypothesis” threshold: the SoP identifies specific factors which “must as a minimum exist before it can be said that a reasonable hypothesis has been raised” connecting the disease (or death) to service (s 9). The instrument does not itself define the phrase “reasonable hypothesis” beyond using it as the threshold phrase; rather, it operationalises that threshold by listing the qualifying factors.

• Temporal and causal framing: most factors require evidence that the factor existed before the clinical onset (or clinical worsening where noted) of carotid artery disease (see repeated wording in s 9). For some conditions and exposures, the SoP specifies time windows, cumulative dose thresholds, or duration-of‑exposure minima (for example: obesity for at least five years within the 20 years before onset, s 9(3); smoking thresholds and cessation‑time cutoffs, ss 9(5)-9(6); exposure to second‑hand smoke with hours thresholds and cessation windows, ss 9(7)-9(8); radiation dose of at least 0.5 sievert to the affected artery, s 9(13); arsenic exposure at ≥50 µg/L drinking water for at least ten years, Schedule 1; MET-based physical inactivity criteria, Schedule 1 and ss 9(10), 9(35)).

• Differentiation between onset and worsening, and pre‑existing disease: the SoP differentiates factors relevant to initial clinical onset and those relevant to clinical worsening (ss 9(1)-9(25) vs 9(26)-9(51)). Section 10(2) makes a jurisdictional rule: the factors in ss 9(26)-9(51) apply only to material contribution to, or aggravation of, carotid artery disease where the disease was suffered or contracted before or during (but did not arise out of) the person’s relevant service. In other words, these latter factors are tailored to claims that the service materially contributed to pre‑existing disease.

• Cross‑reference mechanism: if a factor in s 9 refers to an injury or disease covered by another SoP, then the terms of that other SoP apply (s 11). This creates an explicit mechanism for deferring to other medical SoPs where causation hinges on a related condition.

• Standardised thresholds and measurement rules: Schedule 1 supplies numeric cut‑offs and formulae for measuring BMI (W/H2), defining chronic kidney disease (GFR <60 or markers of renal damage, or transplant), defining pack‑years (20 cigarettes/day for a year or weight equivalents), and providing a methodology reference for cumulative equivalent radiation dose (ARPANSA Guide as at 2 August 2017). These standardised measures reduce ambiguity about what will qualify as a factor in evidentiary terms.

These concepts together mean the SoP is both prescriptive and technical: claimants and decision‑makers must map clinical facts to the instrument’s definitions and time thresholds. The instrument therefore shifts a portion of the evidentiary inquiry into quantifiable, enumerated factors, and onto documentable exposures and clinical findings as defined in Schedule 1 and s 9.

Primary affected persons

• Claimants: current or former members of the Armed Forces whose claims fall under s 120A of the VEA or s 338 of the MRCA are directly affected. Section 5 expressly states the instrument applies to claims to which those provisions apply. The Schedule defines “relevant service” to include operational, peacekeeping, hazardous, British nuclear test defence service under the VEA and warlike or non‑warlike service under the MRCA. Consequently, veterans, reservists and others with qualifying service histories who lodge claims for carotid artery disease or death from it will be assessed against this SoP (s 5; Schedule 1 definition of relevant service).

• Dependants and estates: where death is claimed to have arisen from carotid artery disease, beneficiaries or personal representatives who lodge or pursue death‑related entitlements will be affected because the SoP governs whether a reasonable hypothesis that death was contributed to by carotid disease is raised (see s 7(5)).

Secondary affected persons and entities

• Medical practitioners and experts: clinicians providing medico‑legal evidence, treating practitioners preparing histories and diagnostic records, and medico‑legal experts who prepare opinions for claims must apply the instrument’s definitional thresholds (Schedule 1) and timing windows (s 9). They will need to document exposures, lab results and measurements (for example, cumulative pack‑years, BMI calculations, lipid panels, GFR values, radiation dose reconstructions) in ways that map to the SoP’s criteria.

• Repatriation Medical Authority (RMA) and decision makers: the RMA, which made the instrument under s 196B(2) (s 3), and the Department of Veterans’ Affairs (DVA) decision makers who apply the SoP in determining claims, are affected operationally. The SoP supplies the medical‑scientific basis the RMA has determined to be sound (s 8) and the DVA will use it in adjudication under the VEA and MRCA claims framework.

• Courts and tribunals: Administrative tribunals and courts that review decisions under VEA/MRCA will be affected insofar as they interpret whether decision‑makers applied the SoP correctly, whether evidence meets the listed thresholds, and how the SoP interacts with statutory causation requirements. The text itself contains no litigation history, but the SoP will form part of the factual matrix in reviews.

• Service organisations and legal representatives: veterans’ advocates, lawyers and supportive organisations will need to account for the SoP when advising claimants and gathering evidence.

What is not affected directly by the instrument

• The SoP does not itself change entitlement law under the VEA or MRCA; it is an evidentiary/medical standard used to determine whether a reasonable hypothesis that the condition is related to service has been raised (ss 3, 5, 8-11). It does not impose criminal or civil penalties, nor does it create novel rights outside the claims framework.

• Private insurers and other non‑scheme benefits: while information and standards in the SoP may be of interest, the instrument applies specifically to claims under the VEA and MRCA (s 5). It does not purport to bind private compensation schemes.

Temporal scope and amendment effect

• The SoP took effect on 28 September 2020 (Endnote 3), and was amended by Determination No. 94 of 2022 with effect on 19 September 2022 (Endnote 3). The amendment affected the definition of “one pack‑year” and related notes in ss 9(5), 9(6), 9(30) and 9(31) and the Schedule (Endnote 4). Practitioners must ensure they apply the SoP as in force at the relevant decision time (see compilation notes and endnotes).

Duties created or clarified by the instrument

• Duty to establish factor presence for “reasonable hypothesis”: The principal operative duty for a claimant is to adduce evidence that at least one of the enumerated factors in s 9 “must as a minimum exist” before a reasonable hypothesis linking carotid artery disease or death from it with relevant service can be said to be raised. Evidence must show the factor existed before clinical onset (or clinical worsening when relevant) and that the factor is related to relevant service (s 9; s 10(1)).

• Duty to relate factors to relevant service: Section 10(1) requires that any factor in s 9 relied upon “must be related to the relevant service rendered by the person.” The SoP does not prescribe a single method for proving that relationship, but the requirement is explicit: temporal, causal or exposure links between the factor and the person’s relevant service must be shown.

• Duty to apply the specified definitions and thresholds: Evidence must be mapped against the definitions in Schedule 1. For example, obesity is specified as BMI ≥ 30; chronic kidney disease is an abnormality of kidney structure or function present for at least three months; pack‑years are defined with weight equivalents and the calculation method (Schedule 1). The duty therefore includes producing measurements, clinical test results and records that meet these thresholds.

• Duty in pre‑existing disease cases: Where the person’s carotid artery disease was suffered or contracted before or during (but did not arise out of) the relevant service, the subsection 9(26)-9(51) factors apply solely to claims of material contribution or aggravation (s 10(2)). Claimants must frame their evidence accordingly.

Rights clarified or referenced in the instrument

• Right to have a “reasonable hypothesis” considered using specified medical factors: The SoP affords claimants a clear evidentiary pathway,if one or more specified factors are present and related to service, a reasonable hypothesis may be held to be raised (s 9). The instrument operationalises what is required for that threshold.

• Right to cross‑referenced SoPs: If a factor in s 9 refers to an injury or disease covered by another SoP, then that other SoP applies “in accordance with the terms of that Statement of Principles as in force from time to time” (s 11). This provides a right to have interrelated medical conditions considered under their appropriate SoPs.

• Right to inclusion of death claims where carotid disease contributed: Section 7(5) extends the SoP to death from a terminal event or condition that was contributed to by carotid artery disease. This means that dependants and estates can have death claims assessed under the SoP where the required link to carotid disease is shown.

What the SoP does not do (limits)

• It does not itself confer compensation or benefits,the instrument is an evidentiary tool used in the statutory claims process under the VEA and MRCA (s 5). The actual entitlements, decision processes, and appeal mechanisms are set by the VEA/MRCA and associated procedural law, not by the SoP.

• It does not set procedural obligations on decision‑makers beyond the use of its medical findings as part of the assessment of whether a reasonable hypothesis exists. The SoP does not provide appeal rights, procedural timelines or adjudicative standards beyond its substantive medical definitions.

Evidentiary implications

• The SoP shifts part of the evidentiary burden onto quantifiable, defined criteria. For decision makers and assessing clinicians, this narrows the medical inquiry to whether the claimant’s facts meet the numerical and temporal thresholds in Schedule 1 and s 9, and whether the factor is related to relevant service (s 10(1)). For litigators and advocates, the SoP identifies where medical proof must be specific (e.g., radiation dose reconstructions per ARPANSA methodology, Schedule 1).

No criminal or civil penalties

• The instrument contains no provisions imposing criminal penalties, fines or direct civil liabilities. It is a statutory determination under the VEA used to inform administrative decisions about veteran entitlements (s 3). The text contains no enforcement provisions beyond its operative role in claims assessment.

Administrative enforcement mechanism

• Enforcement is administrative: the practical consequence of the SoP is in administrative decision making under the VEA and MRCA. The RMA made the SoP under s 196B(2) and the SoP is applied by the Department of Veterans’ Affairs and the decision‑makers who determine entitlements under s 120A VEA or s 338 MRCA (s 5). The instrument thereby influences whether a claim is accepted or rejected on the basis that a reasonable hypothesis has or has not been raised.

• Review and appeal pathways are supplied by the VEA/MRCA governance and are not altered by this instrument. While the SoP provides the medical criteria, any legal challenge to a decision that applies the SoP must proceed through the statutory review and appeal mechanisms established by the VEA/MRCA and administrative law, rather than under the SoP itself.

Practical enforcement consequences

• The immediate enforceable effect is practical: if a claimant cannot establish any of the factors in s 9, or cannot establish that the factor is related to relevant service (s 10(1)), then the decision‑maker may find that a reasonable hypothesis of service connection has not been raised and decline to accept service connection for carotid artery disease (or death). Conversely, meeting the SoP’s criteria supports a finding that the medical threshold is met.

• The instrument requires precise documentary proof for many qualifying factors (Schedule 1), for example, demonstrating a cumulative equivalent radiation dose of at least 0.5 sievert to the affected artery (s 9(13) and Schedule 1 reference to the ARPANSA Guide), or evidence of arsenic exposure at specified concentrations over a decade (Schedule 1). The enforcement, therefore, is evidentiary: absence of such proof will affect the administrative outcome.

No express obligations on third parties

• The SoP does not create express statutory obligations on third parties (for example employers, water suppliers, medical practitioners) to produce documents or to notify. The evidence required will typically be collected by claimants through medical records, service records, environmental or occupational records, and medico‑legal reporting.

Documentation and proof standards

• While the SoP dictates what must be shown medically, it does not specify procedural proof standards (for example, the precise standard of admissibility for particular documents) in the text. Those elements are determined under the broader claims framework and administrative law practice.

Direct statutory interaction

• Veterans’ law: The instrument is made under s 196B(2) of the VEA (s 3) and expressly applies to claims to which s 120A of the VEA or s 338 of the MRCA applies (s 5). That locates the SoP within the Part XIA SoP framework used to determine causal connection between injury/disease and service. Its primary legal interaction is therefore with the VEA and MRCA decision‑making framework.

• Cross‑SoP interaction: Section 11 provides an explicit cross‑reference rule: if a factor in s 9 refers to an injury or disease that is itself the subject of another SoP determined under s 196B(2) of the VEA, then the other SoP applies according to its own terms as in force from time to time. This formalises a hierarchy and interdependence among SoPs: where causation or contribution is through another disease, decision makers must consult that disease’s SoP.

Technical and administrative interactions

• ICD‑10‑AM coding: Section 7(3)-(4) notes that while carotid artery disease attracts certain ICD‑10‑AM codes (I65.2, I70.8, I72.0 or I77.0), the legal meaning is the statutory definition in s 7(2). The instrument therefore interacts technically with clinical coding practices but specifies that the statutory definition governs legal application. The ICD reference signals compatibility with clinical classification systems used in medical records.

• Radiation dose methodology: The Schedule’s definition of “cumulative equivalent dose” requires use of the methodology set out in the ARPANSA Guide “as in force on 2 August 2017” (Schedule 1). That links the SoP to a specific technical guide published by the Australian Radiation Protection and Nuclear Safety Agency. For dose reconstruction, decision makers and experts will therefore use that methodology to calculate cumulative organ doses relevant to ss 9(13) and 9(38).

• Exposure thresholds and environmental standards: The Schedule defines “being exposed to arsenic as specified” by reference to consuming drinking water with an average arsenic concentration of at least 50 micrograms per litre for a cumulative period of at least ten years, or equivalent cumulative exposure, or clinical evidence of chronic arsenic toxicity. This interacts implicitly with environmental monitoring records, historical water quality data and public health standards, though the SoP’s threshold is its own internal standard.

Non‑interaction or limits

• The instrument does not displace or amend substantive entitlement criteria in the VEA or MRCA. It supplies medical evidence thresholds for raising a reasonable hypothesis; the ultimate legal entitlement determinations remain governed by the VEA/MRCA and associated procedural law.

• It does not purport to bind non‑scheme decision makers such as private insurers or state tribunals; its legal force is within the federal veterans’ entitlements framework (s 5).

Interpretive interaction risks

• Because the SoP specifies numeric thresholds and technical definitions, it interacts with other regulatory or scientific standards where those standards use different thresholds (for example, environmental arsenic limits, or BMI categorisations). Where external standards differ from the SoP’s thresholds, decision makers must apply the SoP’s definitions as legal criteria in the VEA/MRCA context.

• The cross‑SoP clause (s 11) introduces potential interpretative complexity where multiple SoPs reference one another; coherence depends on ensuring the relevant SoPs’ terms are compatible for the fact pattern.

Registration and commencement

• The primary Statement of Principles concerning carotid artery disease (No. 54 of 2020) was registered on 31 August 2020 and commenced on 28 September 2020 (Endnote 3). The compilation shows the instrument as amended up to the Veterans' Entitlements (Statements of Principles,definition of "one pack-year") Amendment Determination 2022 (No. 94 of 2022) (F2022L01128), with that amendment’s day of commencement being 19 September 2022 (Compilation preface and Endnote 3).

Nature and scope of the 2022 amendment

• The 2022 Amendment Determination No. 94 expressly concerned the definition of “one pack‑year” and consequential notes in the SoP. Endnote 4 records amendments to subsection notes in ss 9(5), 9(6), 9(30) and 9(31) and to the Schedule 1 definition of one pack‑year. The amendment was registered on 26 August 2022 and commenced on 19 September 2022 (Endnote 3). The compilation text shows the updated one pack‑year definition (Schedule 1) which sets an equivalent amount of tobacco products as 7,300 grams of smoking tobacco by weight and gives conversion rules for pipe tobacco, cigars or combinations (Schedule 1).

Other historical editing

• The compilation notes that sections 2 and 4 were repealed by the Legislation Act 2003 specifications (Endnote 4 indicates “Section 2… rep LA s 48D” and “Section 4… rep LA s 48C”). Those repeals are administrative and relate to the compilation formatting or statutory instrument technicalities rather than the substantive criteria for carotid artery disease. The compilation also includes standard notes on endnotes and the compilation process.

Implications of the amendments

• The 2022 amendment focused on refining the one pack‑year measure. The Schedule now contains specific weight‑equivalents and calculation guidance (Schedule 1: “one pack‑year means the amount of tobacco consumed in smoking 20 cigarettes per day for a period of 1 year, or an equivalent amount of tobacco products… an equivalent amount … is 7,300 grams of smoking tobacco by weight, … For pipe tobacco, cigars or combinations … 1 gram of tobacco is considered to be equal to one cigarette. Pack‑years are calculated by dividing the number of cigarettes smoked per day by 20 and multiplying this number by the number of years the person has smoked.”) Endnote 4 shows the places where related notes were updated in s 9.

• Users of the SoP must therefore verify which version applies at the time of the claim decision. The compilation date here is 19 September 2022 and includes the 2022 amendment. The compilation preface reminds readers that uncommenced amendments are not shown and directs users to the Legislation Register for any uncommenced changes.

Record‑keeping and versioning

• The instrument itself contemplates versioning: s 11 refers to other SoPs “as in force from time to time,” and the compilation and endnotes indicate the RMA’s determinations are maintained and amended periodically. Practitioners should therefore consult the current SoP text and relevant amendment history for the date on which a claim is determined.

No cases or judicial determinations are recorded in the instrument

• The text of this Statement of Principles contains no references to judicial or tribunal decisions and does not list any litigation history. The instrument is an administrative determination under s 196B(2) of the VEA (s 3) and the compilation’s endnotes (Endnotes 1-4) list registration and amendment events but do not include any cases.

What that absence implies for practitioners

• Because the instrument itself does not reference any court or tribunal decisions, there is no internal precedent or adjudicative gloss in the SoP compilation text to guide application beyond the statutory wording and Schedule definitions. Any legal interpretation disputes about applying the SoP will be informed by the VEA/MRCA scheme and administrative law principles, but the SoP text provides the primary working rules for medical causation in the context of veterans’ claims.

• Practitioners should therefore rely on the SoP’s wording (ss 7-11 and Schedule 1) and on the relevant VEA/MRCA statutory framework when preparing and litigating claims. External case law that interprets the “reasonable hypothesis” standard, the application of SoPs or the handling of technical evidentiary issues in veterans’ law may exist elsewhere, but such cases are not cited in this instrument and should be sourced independently.

Potential sources of dispute for litigation

• Interpretative disputes that could generate litigation include: whether particular evidence meets Schedule 1 thresholds (for example, reconstructing cumulative equivalent radiation doses using the ARPANSA Guide), whether a factor is temporally connected to clinical onset/worsening as required by s 9, whether the required relationship to relevant service under s 10(1) is established, and how s 11 cross‑references should be applied when a factor points to an injury covered by another SoP.

• The instrument’s technical definitions and numeric thresholds (e.g., 0.5 sievert dose, 50 µg/L arsenic for 10 years, BMI ≥ 30) create concrete, litigable questions about measurement, documentation and interpretation.

Absence of internal dispute resolution mechanics

• The SoP itself does not set out dispute resolution mechanics; disputes about the application of the SoP will be resolved through the established statutory review and appeal pathways under the VEA and MRCA and, where appropriate, by judicial review under administrative law principles.

Candidates for evidentiary pitfalls

• Numerical and duration thresholds are precise and potentially unforgiving. Many factors have strict quantitative thresholds: obesity requires BMI ≥ 30 (Schedule 1); arsenic exposure requires an average drinking water concentration of ≥ 50 µg/L for at least ten years or equivalent cumulative intake (Schedule 1); radiation requires cumulative organ dose ≥ 0.5 sievert (ss 9(13), 9(38) and Schedule 1); second‑hand smoke exposure thresholds are 1,000 hours without cessation and 5,000 hours with cessation or 1,000-5,000 hours with a five‑year cessation cut‑off (ss 9(7)-9(8), 9(32)-9(33)). These specific cut‑offs require precise evidence, which often is not readily available.

• Pack‑year recalculation and conversion rules. The 2022 amendment clarifies pack‑year equivalence: 20 cigarettes per day for one year or an equivalent amount equalling 7,300 grams of smoking tobacco by weight, with 1 gram of pipe/cigar tobacco treated as one cigarette for conversion purposes (Schedule 1). Historic smoking records, self‑reports, or inconsistent notations can make meeting these precise calculations difficult. The instrument requires pack‑years to be calculated in the specified way (Schedule 1; ss 9(5), 9(6), 9(30), 9(31)).

• Demonstrating “related to relevant service.” Section 10(1) requires factors to be related to relevant service. The SoP does not define the level of causal linkage required; therefore proof will typically involve combining service records, exposure logs, occupational histories, deployment records and medical records to show the nexus. This can be difficult, especially where exposures are historical or inadequately recorded.

• “Inability to obtain appropriate clinical management” (s 9(51)) is listed as a factor without a Schedule definition. That introduces interpretive uncertainty: what constitutes “appropriate clinical management,” and how is inability established? Claimants will need to compile evidence of access barriers, referral delays, lack of services in theatre or post‑service, or treatment refusals to support this factor, but the SoP gives no precise standard.

• Time windows for smoking cessation and second‑hand smoke. The SoP distinguishes between ongoing smoking and permanent cessation, and applies different pack‑year thresholds and time‑since‑cessation windows (ss 9(5)-9(6) and 9(30)-9(31)). Practically, this requires precise cessation dates and corroborating documentation to determine which clause applies.

Technical reconstruction burdens

• Radiation dose reconstruction. The Schedule requires dose calculation in accordance with the ARPANSA Guide “as in force on 2 August 2017.” Dose reconstructing at organ/tissue level to establish ≥0.5 sievert to the affected artery will generally require specialist radiation dosimetry expertise and can involve assumptions where service records are incomplete.

• Arsenic exposure evidence. Establishing average arsenic concentration of drinking water over a decade generally requires historical water quality data or occupational/environmental exposure records. The SoP’s threshold (≥50 µg/L for at least ten years) may not align with more conservative public health standards; however, for the SoP, this is the legal test (Schedule 1).

• Physical activity METs. The SoP’s inactivity criteria require that the person was unable to undertake activity greater than three METs for at least five years within the 20 years before clinical onset/worsening (ss 9(10), 9(35) and Schedule 1 definition of MET). Translating everyday function and occupational duties into METs over historical periods can be challenging and requires clinical assessment and possibly occupational task analysis.

Narrow scope and conditional applicability

• Distinction between onset and worsening, and pre‑existing disease limitation. If carotid artery disease was suffered or contracted before or during (but did not arise out of) the person’s relevant service, only the ss 9(26)-9(51) factors apply to claims of material contribution/aggravation (s 10(2)). That means claimants and advisors must precisely frame whether the claim is for causation of onset or for aggravation. Mischaracterising the claim could lead to reliance on incorrect sets of factors.

• ICD‑10‑AM codes noted but statutory meaning overridden. Section 7(3) notes the ICD‑10‑AM codes that “attract” to carotid disease but expressly states the legal meaning for the instrument is s 7(2). Clinical coders’ label alone is not decisive; the statutory definition governs, and administrative decision makers will apply the legal definition.

Cross‑SoP complications

• If a factor in s 9 refers to a disease covered by another SoP, that other SoP’s terms govern (s 11). This can create multi‑instrument evidence work and potential timing mismatch if the other SoP has different thresholds or was amended at different times.

Record scarcity and evidentiary mismatch

• Many veterans’ claims involve events decades earlier or in theatres where records are incomplete. Several s 9 factors require precise historical data (occupational/aircrew radiation exposure, water supply arsenic concentrations, cumulative smoking history, second‑hand smoke hours, dietary averages over five consecutive years). The practical difficulty of assembling such records is a recurring “gotcha”.

Gather evidence mapped to each s 9 factor and Schedule definitions

• Use a factor‑by‑factor checklist. For each claimed factor in s 9, prepare documentary evidence that ties the factor to the individual and the relevant service period, and that meets the Schedule’s numeric or qualitative definitions where applicable. Below are specific evidence types mapped to selected high‑use factors:

  • Hypertension (ss 9(1), 9(26)): Provide serial blood pressure readings, antihypertensive prescriptions and primary care or specialist notes showing diagnosis and dates demonstrating hypertension prior to clinical onset/worsening.

  • Diabetes mellitus (ss 9(2), 9(27)): Provide diagnostic records, HbA1c/elevated glucose labs, medications and dates indicating diabetes diagnosis prior to onset/worsening.

  • Obesity (ss 9(3), 9(28) and Schedule 1): Provide weight and height records to compute BMI over time (W/H2 formula in Schedule 1), showing BMI ≥ 30 for at least five years within the 20 years before clinical onset/worsening.

  • Dyslipidaemia (ss 9(4), 9(29) and Schedule 1): Provide lipid panels with values meeting any Schedule thresholds (HDL <1.0 mmol/L; LDL >4.0 mmol/L; triglycerides ≥2.0 mmol/L; total cholesterol >5.5 mmol/L) or records of regular lipid‑lowering medication.

  • Smoking/pack‑years (ss 9(5)-9(6), 9(30)-9(31) and Schedule 1): Prepare a detailed smoking history with dates, amounts and cessation dates. Calculate pack‑years per Schedule 1: divide cigarettes per day by 20 and multiply by years smoked; convert other tobacco products using the weight equivalence rules (7,300 grams = one pack‑year equivalence as specified). Corroborate via medical records, employment health checks or self‑report corroborated by family.

  • Second‑hand smoke exposure (ss 9(7)-9(8), 9(32)-9(33) and Schedule 1): Document locations and durations in enclosed spaces (e.g., shipboard berths, barracks, mess rooms, vehicles) and estimate cumulative exposure hours; provide witness statements or contemporaneous records where possible.

  • Radiation exposure (ss 9(13), 9(38) and Schedule 1): Commission a cumulative equivalent dose reconstruction using the ARPANSA Guide methodology specified in Schedule 1 (as in force on 2 Aug 2017). Collect service role records (e.g., aircrew logs, service on vessels involved with nuclear tests, medical radiology histories, radiotherapy records including field of radiation).

  • Arsenic exposure (ss 9(20), 9(45) and Schedule 1): Where drinking water exposure is claimed, obtain historical water quality data for the locations in question, occupational/environmental exposure records, or clinical evidence of chronic arsenic toxicity. Document durations to meet the ten‑year cumulative threshold.

  • Infection, autoimmune diseases, periodontitis (ss 9(9), 9(15), 9(16), 9(17), 9(18), 9(40), 9(41), 9(42), 9(43)): Collect microbiology, serology, specialty clinic notes, dental records, biopsy or imaging reports. For periodontitis, document length of disease and treatment records over the two‑year minimum.

  • Trauma and surgical events (ss 9(23), 9(48) and Schedule definitions): Provide operative notes, imaging showing injury or surgical intervention to the affected artery, or contemporaneous medical reports. For neck/base of skull trauma relevant to dissection (s 9(24)(a), s 9(49)(a)), provide emergency or hospital records showing mechanism and timing within six months.

  • Postpartum timing for internal carotid dissection (ss 9(22), 9(47)): Provide obstetric records confirming delivery dates and the fact the dissection occurred within 30 days postpartum.

  • Drug exposures (ss 9(24)(b), 9(25), 9(50) and Schedule 1 specified drugs): Provide prescription records, toxicology reports, hospital medication charts, or credible witness statements documenting drug ingestion within the required time windows (e.g., fluoroquinolone within 30 days before onset/worsening; specified listed drugs within four days for certain aneurysm/dissection claims).

  • Diet and fruit/vegetable consumption (ss 9(14), 9(39)): Evidence of inability to consume an average of at least 100 grams per day of fruit/vegetables for five consecutive years within 20 years prior , typically clinic nutrition assessments, dietitian notes or corroborating accounts.

  • METs physical activity index (ss 9(10), 9(35) and Schedule 1): Provide functional assessments, exercise tolerance tests, clinician assessments translated into MET levels, and occupational duty descriptions. Specialist cardiopulmonary testing reports where available are useful.

  • Chronic kidney disease (ss 9(11), 9(36) and Schedule 1): Provide GFR reports showing <60 mL/min/1.73 m2 for at least three months, imaging, biopsy or albuminuria evidence, or transplant records.

  • Obstructive sleep apnoea (ss 9(21), 9(46)): Provide sleep study/polysomnography results and diagnosis with timing at least one year prior to onset/worsening.

  • “Inability to obtain appropriate clinical management” (s 9(51)): Assemble records of referrals, service availability in theatre, delays, denials, communications with health services, and contemporaneous notes showing missed or unavailable care.

Frame the link to relevant service

• For each claimed factor, prepare evidence that links the factor to the person’s relevant service as per s 10(1): deployment records, unit logs, medical treatment records while on service, environmental monitoring data from specific postings, witness statements from contemporaries, and official records showing presence in locations or roles likely to involve the exposure.

• For pre‑existing disease cases where aggravation/material contribution is claimed, ensure evidence maps to ss 9(26)-9(51) and that the disease timeline confirms the disease was suffered or contracted before or during relevant service but did not arise out of service (s 10(2)).

Use the Schedule definitions precisely

• Use the Schedule’s numeric cut‑offs and formulae as evidentiary checklists. For BMI use the W/H2 formula provided in Schedule 1. For pack‑years use the description and conversion metrics supplied. For radiation/dose use the ARPANSA Guide methodology cited in Schedule 1.

Address cross‑SoP references early

• If any factor refers to another SoP’s disease, identify that SoP and collect the evidence required by it (s 11). Cross‑SoP links can create additional documentary requirements and time windows; treating clinicians and experts should be instructed to address any overlapping SoP criteria in their reporting.

Prepare expert reports tailored to the SoP

• Medical experts should be instructed to expressly address the SoP: state whether the claimant meets the specific s 9 factor(s) and Schedule thresholds, provide dates and documentary references for onset/worsening, and explain how the factor is related to relevant service (s 10(1)). For technical reconstructions (radiation, arsenic), use appropriately credentialed specialists and methodologies referenced in the SoP.

Anticipate evidentiary weaknesses and prepare corroboration

• Where direct records are unavailable, gather corroborating secondary evidence: service diaries, unit logs, contemporaneous statements from colleagues, postal or accommodation records, and any environmental monitoring. For exposure hours (second‑hand smoke), assemble contextual documentation of living or working conditions showing regular enclosed exposure.

Version control and date of decision

• Confirm which version of the SoP is in force at the date the decision is made. The compilation shows amendments up to 19 September 2022 (Endnote 3). Use the SoP version effective on the decision date for assessing whether the claimant meets thresholds, and record the version in submissions.

Checklist and record template

• Create a claim file template listing each s 9 factor (1-51), the Schedule definition applicable, the evidence required (labs, imaging, service records, specialist reports), the relevant service connection evidence (deployment dates, duties), and a space for expert opinion explicitly mapping the evidence to the SoP wording. This reduces the risk of missing precise thresholds (e.g., five years in 20, 1,000 vs 5,000 hours, 0.5 sievert, 50 µg/L × ten years).

Engage early with DVA procedures

• While the SoP governs the medical criteria, the procedural steps for lodging, progressing and reviewing claims follow the VEA/MRCA routes. Ensure claims are lodged and progressed under the correct statutory sections (s 120A VEA or s 338 MRCA) and that documentary evidence is provided in the formats required by DVA.